|
The U.S. Food and Drug Administration (FDA) continued to take action in the ongoing response to the COVID-19 pandemic:
- Today, to help protect consumers from methanol poisoning, the FDA issued a new guidance,“Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol, Including During the Public Health Emergency (COVID-19),” to notify drug manufacturers and compounders of FDA’s policy on certain testing procedures on all lots of alcohol and isopropyl alcohol prior to manufacturing to prevent methanol contamination or substitution in drugs. Methanol is not an acceptable ingredient for any drug product and should not be used due to its toxic effects.
- To accelerate the adoption of advanced and smart manufacturing technologies to help strengthen the nation’s public health infrastructure, the FDA created a new collaboration with the National Institute of Standards and Technology (NIST) through a memorandum of understanding (MOU). This MOU is intended to increase U.S. medical supply chain resilience and advanced domestic manufacturing of pharmaceuticals, biopharmaceuticals and medical devices—including those necessary to fight the COVID-19 pandemic—through adoption of 21st century manufacturing technologies. These include smart technologies, such as artificial intelligence and machine learning, and emerging manufacturing processes. The MOU signals alignment between senior leadership at both institutions in recognition of the importance of modernizing regulatory frameworks as well as industry practices to meet public health needs in the U.S.
- The FDA updated its “Investigational COVID-19 Convalescent Plasma” guidance and corresponding webpage. The revisions provide recommendations regarding when individuals who have received an investigational COVID-19 vaccine as a participant in a clinical trial, or received an authorized or licensed COVID-19 vaccine, qualify as convalescent plasma donors. In addition, the agency has extended the period of enforcement discretion described in the guidance.
- The FDA also posted updated information on its website for blood establishments regarding the COVID-19 pandemic and blood donation.
- Testing updates:
- As of today, 319 tests and sample collection devices are authorized by the FDA under emergency use authorizations (EUAs). These include 237 molecular tests and sample collection devices, 69 antibody tests, and 13 antigen tests. There are 32 molecular authorizations that can be used with home-collected samples. There is one molecular prescription at-home test, one antigen prescription at-home test, and one over-the-counter (OTC) at-home antigen test.
Additional Resources:
|
|
|
|
